An anti-MSLN CD4+ T cell response was observed in 84% of pancreatic cancer patients (21 out of 25), 66.7% of patients with benign disease (10 out of 15) and 43.7% of healthy donors (7 out of 15). Here, MSLN is linked to familial pancreatic carcinoma.